May 11, 2020 / 12:41 PM / 23 days ago

BRIEF-Passage Bio Reports Q1 2020 Financial Results

May 11 (Reuters) - Passage Bio Inc:

* PASSAGE BIO REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

* Q1 LOSS PER SHARE $1.00

* Q1 EARNINGS PER SHARE ESTIMATE $-0.45 — REFINITIV IBES DATA

* ORPHAN DRUG DESIGNATION RECENTLY GRANTED BY FDA FOR LEAD DEVELOPMENT CANDIDATE PBGM01

* PROGRAM EXPECTED TO ENTER CLINIC FOR TREATMENT OF INFANTILE GM1 IN Q4 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below